Alopecia as an Emerging Adverse Effect Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists for Weight Loss: A Scoping Review
Rojas Lopez RF., Lynett Barrera D., Amaya Muñoz MC., Saavedra Diaz MP.
Clinical Trial on Hair Loss, published in Cureus (2025) — summary generated from the PubMed abstract.
Several human studies show positive signals, while research methods and sample sizes continue to develop.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Clinical Trial
- Journal
- Cureus (2025)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 40951222
- PMCID
- PMC12431796
- DOI
- 10.7759/cureus.90021
- Citations
- 1
Abstract (original English)
Alopecia has recently been reported as a potential emerging adverse effect associated with glucagon-like peptide-1 receptor agonists (GLP-1RAs), which are widely prescribed for weight loss. While gastrointestinal symptoms remain the most frequently documented adverse effects, an increasing number of reports describe hair loss events in patients treated with semaglutide, liraglutide, tirzepatide, and dulaglutide. This scoping review aimed to synthesize the available evidence regarding this potential association. A systematic literature search was conducted across PubMed, Scopus, Google Scholar, Cochrane, and the Latin American and Caribbean Literature on Health Sciences (LILACS) database through May 24, 2025. Nine studies met the inclusion criteria, comprising randomized clinical trials, cohort studies, and pharmacovigilance analyses. Most studies lacked dermatological diagnostic confirmation, and only one described the clinical pattern of alopecia, identifying telogen effluvium and androgenetic alopecia as the most frequent subtypes. The findings suggest that GLP-1RAs may alter the hair follicle cycle. More than 1,000 spontaneous cases have been reported in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS). Although a causal relationship cannot be confirmed, the recurrence of cases across diverse settings signals a potential safety concern that warran
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Several human studies show positive signals, while research methods and sample sizes continue to develop.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level ASystematic ReviewEurope PMC
The suitability of mesenchymal stem cells for treating immune-mediated inflammatory skin diseases: a systematic review
Systematic Review with a reported sample of 609 on Hair Loss, Immune Modulation, Autoimmune Research, published in Dermatol Reports (2026) — summary generated from the PubMed abstract.
- 2026
- n = 609
Dermatol Reports - Level ASystematic ReviewPubMed
A systematic review of clinical evidence on the efficacy and safety of conditioned media, platelet-rich fibrin, stromal vascular fraction, extracellular vesicles, and stem cells in androgenetic alopecia.
Systematic Review with a reported sample of 724 on Hair Loss, Hair Regeneration, published in Stem Cell Res Ther (2026) — summary generated from the PubMed abstract.
- 2026
- n = 724
Stem Cell Res Ther - Level AMeta-analysisEurope PMC
DKK3-CKAP4 signaling drives fibroimmune remodeling and hair follicle miniaturization in androgenetic alopecia
Meta-analysis on Hair Loss, Hair Regeneration, published in Theranostics (2026) — summary generated from the PubMed abstract.
- 2026
Theranostics - Level AMeta-analysisEurope PMC
Systematic review and meta-analysis of the use of micrografting technology in humans
Meta-analysis with a reported sample of 24 on Chronic Wound, Burns, Hair Loss, published in J Int Med Res (2025) — summary generated from the PubMed abstract.
- 2025
- n = 24
J Int Med Res1 citations - Level ASystematic ReviewEurope PMC
Therapeutic potential of stem cell-derived exosomes in hair regeneration: A systematic review
Systematic Review on Hair Loss, Hair Regeneration, published in World J Stem Cells (2025) — summary generated from the PubMed abstract.
- 2025
World J Stem Cells2 citations - Level ASystematic ReviewPubMed
Exosomes and Hair Regeneration: A Systematic Review of Clinical Evidence Across Alopecia Types and Exosome Sources.
Systematic Review on Hair Loss, Hair Regeneration, published in Clin Cosmet Investig Dermatol (2025) — summary generated from the PubMed abstract.
- 2025
Clin Cosmet Investig Dermatol6 citations